

PROP

PHYSICIANS FOR RESPONSIBLE OPIOID PRESCRIBING

2012 JUL 26 P 1:48

July 25, 2012

Dockets Management Branch
Food and Drug Administration
Room 1061
5630 Fishers Lane
Rockville MD 20852

The undersigned clinicians, researchers and health officials from fields that include Pain, Addiction, Primary Care, Internal Medicine, Anesthesiology, Psychiatry, Neurology, Emergency Medicine, Toxicology, Rheumatology, and Public Health submit this petition under Section 21 CFR 10.20 and 21 CFR 10.30 and other pertinent sections of the Federal Food, Drug and Cosmetic Act or any other statutory provision which authority has been delegated to the FDA Commissioner to regulate labeling of opioid analgesics.

At present, the FDA-approved indication for nearly all instant-release opioid analgesics is "moderate to severe pain". For extended-release opioids, the indication is for "moderate to severe pain when a continuous, around-the clock analgesic is needed for an extended period of time." These overly broad indications imply a determination by FDA that they are safe and effective for long-term use. As outlined below, an increasing body of medical literature suggests that long-term use of opioids may be neither safe nor effective for many patients, especially when prescribed in high doses.

Unfortunately, many clinicians are under the false impression that chronic opioid therapy (COT) is an evidence-based treatment for chronic non-cancer pain (CNCP) and that dose-related toxicities can be avoided by slow upward titration. These misperceptions lead to over-prescribing and high dose prescribing. By implementing the label changes proposed in this petition, FDA has an opportunity to reduce harm caused to chronic pain patients as well as societal harm caused by diversion of prescribed opioids. In addition, FDA will be able to reinforce adherence to dosing limits that have been recommended by the United States Centers for Disease Control¹, the state of Washington² and the New York City Department of Health and Mental Hygiene³.

The Federal Food, Drug and Cosmetic Act established that a drug intended to treat a condition must be proven safe and effective for use as labeled.⁴ The current label on opioid analgesics does not comply with this law. By taking the actions requested in this petition, FDA will be able to exercise its regulatory responsibility over opioid manufacturers by prohibiting the marketing of opioids for conditions in which their use has not been proven safe and effective.

PRESIDENT
ANDREW KOLODNY, MD
BROOKLYN, NY

VICE PRESIDENT
MICHAEL VON KORFF, ScD
SEATTLE, WA

TREASURER
ROSEMARY ORR, MD
SEATTLE, WA

SECRETARY
STEPHEN GELFAND, MD
MYRTLE BEACH, SC

JANE BALLANTYNE, MD
SEATTLE, WA

IRFAN DHALLA, MD, MSc
TORONTO, ON

GARY FRANKLIN, MD, MPH
SEATTLE, WA

PETE JACKSON
ARLINGTON HEIGHTS, IL

DAVID JUURLINK, MD, PhD
TORONTO, ON

PETROS LEVOUNIS, MD, MA
NEW YORK, NY

LEN PAULOZZI, MD, MPH
ATLANTA, GA

JON STRELTZER, MD
HONOLULU, HI

BETTS TULLY
CHICAGO, IL

ART VAN ZEE, MD
ST. CHARLES, VA

FDA-2012-P-0818

2012-6360

CP

SPECIFIC ACTIONS REQUESTED FOR CHANGES TO OPIOID ANALGESIC LABELS:


1. Strike the term “moderate” from the indication for non-cancer pain.
2. Add a maximum daily dose, equivalent to 100 milligrams of morphine for non-cancer pain.
3. Add a maximum duration of 90-days for continuous (daily) use for non-cancer pain.

STATEMENTS OF SCIENTIFIC BASIS FOR PETITION:


1. Over the past decade, a four-fold increase in prescribing of opioid analgesics has been associated with a four-fold increase in opioid related overdose deaths and a six-fold increase in individuals seeking treatment for addiction to opioid analgesics.⁵
2. Prescribing of opioids increased over the past 15 years in response to a campaign that minimized risks of long-term use for CNCP and exaggerated benefits.^{6,7,8}
3. Long-term safety and effectiveness of managing CNCP with opioids has not been established.⁹
4. Recent surveys of CNCP patients receiving COT have shown that many continue to experience significant chronic pain and dysfunction.^{10,11}
5. Recent surveys using DSM criteria found high rates of addiction in CNCP patients receiving COT.^{12,13}
6. A large sample of medical and pharmacy claims records found that two-thirds of patients who took opioids on a daily basis for 90 days were still taking opioids five years later.¹⁴
7. Patients with mental health and substance abuse co-morbidities are more likely to receive COT than patients who lack these risk factors, a phenomenon referred to as *adverse selection*.¹⁵
8. Three large observational studies published in 2010 and 2011 found dose-related overdose risk in CNCP patients on COT.^{16,17,18}
9. COT at high doses is associated with increased risk of overdose death¹⁸, emergency room visits¹⁹ and fractures in the elderly²⁰.

There is no environmental impact associated with this Citizen’s Petition and we wish to be excluded under 21 CFR Sec. 25.24.


The undersigned certifies, that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petition which are unfavorable to the petition (21 CFR Sec.10.30b).




Jane C. Ballantyne, MD, FRCA
UW Professor of Education and Research
Department of Anesthesiology and Pain Medicine
Seattle, Washington




Miles Belgrade, MD
Medical Director, Fairview Pain Center
Adjunct Professor, Department of Neurology,
University of Minnesota Medical Center
Minneapolis, Minnesota




Russ Carlisle, MD
Medical Director, Emergency Department
Swedish Cherry Hill Medical Center
Seattle, Washington



Roger Chou, MD, FACP
Associate Professor of Medicine
Dept. of Medicine and Dept. of Medical
Informatics and Clinical Epidemiology
Oregon Health & Science University




Edward C. Coyington, MD
Director, Neurological Center for Pain
Cleveland Clinic
Cleveland, Ohio




Robert W. Day, MD, PhD
President Emeritus
Fred Hutchinson Cancer Research Center
Seattle, Washington



Richard A. Deyo, MD, MPH
Kaiser Permanente Professor of Evidence-Based
Family Medicine, Dept. of Family Medicine
Department of Medicine Director, OCTRI
Community and Practice Research Program
Oregon Health and Science University



Irfan Dhalla, MD, MSc
Assistant Professor, University of Toronto
Toronto, Ontario




Thomas A. Farley, MD, MPH
Commissioner, Department of Health
City of New York




Gary M. Franklin, MD, MPH
Research Professor, University of Washington
Director, Occupational Epidemiology and Health
Outcomes Program
Seattle, Washington



Stephen G. Gelfond, MD, FACP
Secretary, Physicians for Responsible Opioid
Prescribing
Myrtle Beach, South Carolina




Stuart Gitlow, MD, MBA, MPH, FAPA
Acting President
American Society of Addiction Medicine
Chevy Chase, Maryland



Roland W. Gray, MD, FASAM
Medical Director, Tennessee Medical Foundation
Physician's Health Program
Brentwood, Tennessee




Erik Gunderson, MD, FASAM
Assistant Professor, Dept. of Psychiatry &
Neurobehavioral Sciences and Dept. of Medicine
Director, Clinical Pharmacological Research Unit
University of Virginia




W. Michael Hooten, MD
Associate Professor of Anesthesiology
Mayo Clinic
Rochester, Minnesota




David Juurlink, MD, PhD
Head, Division of Clinical Pharmacology and
Toxicology, University of Toronto
Toronto, Ontario




Andrew Kolodny, MD
President, Physicians for Responsible Opioid
Prescribing; Chair, Dept. of Psychiatry
Maimonides Medical Center
Brooklyn, New York




Thomas R. Kosten, MD
Waggoner Chair and Professor of Psychiatry,
Neuroscience, Pharmacology
Baylor College of Medicine,
Michael E DeBakey VAMC
Houston, Texas




Kurt Kroenke, MD
Professor of Medicine, Indiana University Research
Scientist, VA HSR&D Center for Implementing
Evidence-Based Practice, Regenstrief Institute
Indianapolis, Indiana




Eric B. Larson, MD, MPH
Vice President for Research, Group Health
Exec. Director, Group Health Research Institute
Seattle, Washington




Petros Levounis, MD, MA
Director, The Addiction Institute of New York
Associate Chair for Clinical Services, Dept. of
Psychiatry, St. Luke's & Roosevelt Hospitals
New York, New York



Elinore F. McCance-Katz, MD, PhD
Professor, Department of Psychiatry
University of California San Francisco
San Francisco, California




Lewis Nelson, MD
Associate Professor, Dept. of Emergency Medicine
New York University School of Medicine
New York, New York




Rosemary Orr, MD
Professor of Anesthesiology, Seattle Children's
Hospital and University of Washington
Seattle, Washington




William Phillips, MD, MPH, FAAP
Theodore J. Phillips Endowed Professor in Family
Medicine, University of Washington
Seattle, Washington




Charles Reznikoff, MD
Internal Medicine and Addiction Medicine,
Hennepin County Medical Center
Minneapolis, Minnesota




Roger Rosenblatt, MD, MPH, MFR
Professor & Vice Chair, Dept. of Family Medicine
University of Washington School of Medicine
Seattle, Washington




Nirav R. Shah, MD, MPH
Commissioner
New York State Department of Health
Albany, New York



Harris Silver, MD
Policy Analyst, Senate Memorial 18 New Mexico
Drug Policy Task Force, Robert Wood Johnson
Foundation Center for Health Policy
University of New Mexico




Kurt C. Stange, MD, PhD
Professor of Family Medicine & Community
Health, Epidemiology & Biostatistics, Oncology
and Sociology, Case Western Reserve University
Cleveland, Ohio




Jon Streltzer, MD
Program Director, Addiction Psychiatry
Professor of Psychiatry, University of Hawaii
Honolulu, Hawaii




Mark Sullivan, MD, PhD
Professor, Dept. of Psychiatry and Behavioral
Sciences; Adjunct Professor Bioethics and
Humanities; Adjunct Professor, Anesthesiology
and Pain Medicine University of Washington
Seattle, Washington




Barbara J. Turner MD, MSED, MA, MACP
Professor of Medicine; Director, ReACH Center
Director, Health Outcomes Improvement
University of Texas Health Science Center
San Antonio, Texas



Judith Turner, PhD
Professor, University of Washington, Dept. of
Psychiatry and Behavioral Sciences



Michael Von Korff, ScD
Senior Investigator
Group Health Research Institute
Seattle, Washington



Sidney M. Wolfe, MD
Director
Public Citizen's Health Research Group
Washington, DC



Art Van Zee, MD
Stone Mountain Health Services
St. Charles Clinic
Charles, Virginia

REFERENCES

1. Centers for Disease Control (CDC). Poison Issue Brief: Unintentional Drug Poisoning in the United States, 2007. Available online at <http://www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdf>
2. Agency Medical Directors' Group. Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain. Washington State Agency Medical Directors' Group: 2010. Available online at <http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf>
3. Paone D, Dowell D, Heller D. Preventing misuse of prescription opioid drugs. City Health Information. 2011;30(4):23-30. Available online at <http://www.nyc.gov/html/doh/downloads/pdf/chi/chi30-4.pdf>
4. Hamburg MA. Innovation, regulation, and the FDA. N Engl J Med 2010;363:2228-2232.
5. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008. Morbidity and Mortality Weekly Report. 2011 Nov 1; 60:1-6.
6. U.S. General Accounting Office: Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem (GAO-04-110), Washington, DC, U.S. General Accounting Office, 2004
7. Van Zee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health 2009;99:221-7.
8. Suffolk County Supreme Court Special Grand Jury. Grand Jury Report: CPL 190.85(1)(C): April 2012. Available online: <http://www.suffolkcountyny.gov/Portals/da/PDFs/webdoc/diversion%20and%20dissemination%20of%20controlled%20substances.pdf>
9. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C; American Pain Society – American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic non-cancer pain. J Pain 2009; 10:113-130.
10. Sullivan MD, Von Korff M, Banta-Green C, Merrill JO, Saunders K. Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. Pain. 2010 May;149(2):345-53.
11. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain. An epidemiological study. Pain 2006;125:172-9.
12. Boscarino JA, Rutstalis M, Hoffman SN, Han JJ, Erlich PM, Gerhard GS, Stewart WF. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system Addiction 2010; 105:1776-1782.
13. Boscarino JA, Rukstalis MR, Hoffman SN, et al. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria. J Addict Dis. 2011;30:185-194.
14. Martin BC, Fan MY, Edlund MJ, Devries A, Braden JB, Sullivan MD. Long-term chronic opioid therapy discontinuation rates from the TROUP study. J Gen Intern Med. 2011;26(12):1450-1457.

15. Edlund MJ, Fan MY, DeVries A, Braden JB, Martin BC, Sullivan MD. Trends in use of opioids for chronic non-cancer pain among individuals with mental health and substance use disorders: the TROUP Study. *Clin J Pain* 2010;26:1-8.
16. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Opioid prescriptions for chronic pain and overdose: a cohort study. *Annals of Internal Medicine* 2010;152:85-92.
17. Bohnert AS, Valenstein M, Bair MJ, et al. (2011). Association between opioid prescribing patterns and opioid overdose-related deaths. *JAMA*, 305:1315-21.
18. Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. *Arch Intern Med* 2011;171: 686–91.
19. Braden JB, Russo J, Fan MY, et al. Emergency department visits among recipients of chronic opioid therapy. *Arch Intern Med* 2010;170:1425-32.
20. Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. *J Gen Intern Med* 2010;25:310-5.

FedEx US Airbill

Express

FedEx
Tracking
Number

8685 1129 6711

1 From This portion can be removed for Recipient's records.

Date

7/25/12

FedEx Tracking Number

868511296711

Sender's
Name

Hudson Lodging LLC

Phone

312-343-6165

Company

MMC/PSYCHIATRY 17400

Address

920 48TH ST

City

BROOKLYN

State

NY

ZIP

11219-2918

Dept./Floor/Suite/Room

1510

2 Your Internal Billing Reference

3 To

Recipient's
Name

Rockledge Medical Center

Phone

Company

Rockledge Medical Center

Recipient's
Address

5630 Fishers Lane Room 1061

We cannot deliver to P.O. boxes or P.O. ZIP codes.

Dept./Floor/Suite/Room

Address

To request a package be held at a specific FedEx location, print FedEx address here.

City

Kirkville

State

MD

ZIP

20852

0396527684



8685 1129 6711

Form
ID No.

0215

Recipient's Copy

4a Express Package Service

☒ FedEx Priority Overnight
Next business morning.* Friday
shipments will be delivered on Monday
unless SATURDAY Delivery is selected.

☐ FedEx Standard Overnight
Next business afternoon.*
Saturday Delivery NOT available.

Packages up to 150 lbs.

☐ FedEx First Overnight
Earliest next business morning
delivery to select locations.*
Saturday Delivery NOT available.

☐ FedEx 2Day
Second business day.* Thursday
shipments will be delivered on Monday
unless SATURDAY Delivery is selected.

☐ FedEx Express Saver
Third business day.*
Saturday Delivery NOT available.

FedEx Envelope rate not available. Minimum charge: One-pound rate.

* To select locations.

4b Express Freight Service

☐ FedEx 1Day Freight*
Next business day.** Friday
shipments will be delivered on Monday
unless SATURDAY Delivery is selected.

☐ FedEx 2Day Freight
Second business day.* Thursday
shipments will be delivered on Monday
unless SATURDAY Delivery is selected.

Packages over 150 lbs.

☐ FedEx 3Day Freight
Third business day.**
Saturday Delivery NOT available.

* Call for Confirmation.

** To select locations.

5 Packaging

☐ FedEx
Envelope*

☐ FedEx Pak*
Includes FedEx Small Pak,
FedEx Large Pak, and FedEx Sturdy Pak.

☐ FedEx
Box

☐ FedEx
Tube

☐ Other

* Declared value limit \$500.

6 Special Handling

Include FedEx address in Section 3.

☐ SATURDAY Delivery
Not available for
FedEx Standard Overnight,
FedEx First Overnight, FedEx Express
Saver, or FedEx 3Day Freight.

☐ HOLD Weekday
at FedEx Location
Not available for
FedEx First Overnight.

☐ HOLD Saturday
at FedEx Location
Available ONLY for FedEx Priority
Overnight and FedEx 2Day
to select locations.

Does this shipment contain dangerous goods?

One box must be checked.

☐ No

☐ Yes
As per attached
Shipper's Declaration.

☐ Yes
Shipper's Declaration
not required.

☐ Dry Ice

Dry ice, 9 UN 1845

kg

Dangerous goods (including dry ice) cannot be shipped in FedEx packaging.

☐ Cargo Aircraft Only

7 Payment Bill to:

Enter FedEx Acct. No. or Credit Card No. below.

Obtain Recip.

☐ Sender
Acct. No. in Section
1 will be billed.

☐ Recipient

☐ Third Party

☐ Credit Card

☐ Cash/Check

Total Packages

Total Weight

Credit Card Auth.

†Our liability is limited to \$100 unless you declare a higher value. See the current FedEx Service Guide for details.

8 Residential Delivery Signature Options

If you require a signature, check Direct or Indirect.

☐ No Signature
Required
Package may be left
without obtaining a
signature for delivery.

☐ Direct Signature
Someone at recipient's
address may sign for
delivery. Fee applies.

☐ Indirect Signature
If no one is available at
recipient's address, someone
at a neighboring address may
sign for delivery. Fee applies.

519

Rev. Date 10/09-Part #198279-©1994-2008 FedEx-PRINTED IN U.S.A.-SRS